{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Substance P",
    "short_name": "Substance P",
    "aliases": [],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "status": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-20",
      "human_use_note": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "evidence_refs": []
        }
      ],
      "use_cases": [
        {
          "text": "These are the most common real-world reasons people look into this peptide, plus the context that tends to matter most (quality, expectations, and safety).",
          "title": "Use cases (real-world)"
        },
        {
          "text": "• research relevance in pain and neuroinflammation pathways"
        },
        {
          "text": "• physiology relevance in nausea and sensory signaling"
        },
        {
          "text": "• often mentioned in inflammation/pain discussions (claims can be speculative)"
        }
      ],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [
        {
          "text": "Interactions here are category flags — they’re meant to help you ask better questions and avoid obvious conflicts. They are not a dosing guide.",
          "title": "Interaction summary"
        },
        {
          "text": "Drug-class flags to review:"
        },
        {
          "text": "• neuropeptide-cns-context"
        },
        {
          "text": "If you’re on cardiovascular, anticoagulant/antiplatelet, serotonergic, or immunomodulating meds/supplements, treat uncertainty as a reason to slow down and verify with a clinician."
        }
      ],
      "current_outlook_bullets": [
        "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-20",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Substance P",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_cognition_mood"
      ]
    },
    "slug": "substance-p"
  },
  "interactions": {
    "drug_classes": [
      "neuropeptide-cns-context"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "Substance P is a neuropeptide involved in pain signaling, inflammation, and nausea pathways. It is not a wellness peptide; altering neuroimmune signaling outside research can carry real risk.",
    "benefits": [
      "research relevance in pain and neuroinflammation pathways",
      "physiology relevance in nausea and sensory signaling",
      "often mentioned in inflammation/pain discussions (claims can be speculative)"
    ],
    "side_effects_common": [
      "flushing or warmth",
      "headache",
      "nausea",
      "lightheadedness"
    ],
    "side_effects_serious": [
      "severe shortness of breath or wheezing",
      "fainting or collapse",
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)"
    ],
    "who_should_be_cautious": [
      "people with asthma or airway reactivity",
      "people with significant cardiovascular disease or frequent fainting",
      "pregnant or breastfeeding individuals",
      "adolescents (high consequence plus inappropriate for non-clinical use)"
    ],
    "schema_version": "practical_block_v1"
  }
}
